Continuous Positive Airway Pressure (CPAP) After Adenotonsillectomy in Children

Not Applicable

Completed

• Conditions: Disorders of Excessive Somnolence; Sleep Apnea Syndromes; Child Behavior Disorders; Sleep Apnea, Obstructive; Attention Deficit Disorder With Hyperactivity
• Interventions: Procedure: CPAP treatment; Other: No CPAP treatment

• Registration Number: NCT01554527
• Lead Sponsor: University of Michigan

Brief Summary

Obstructive sleep-disordered breathing (SDB) affects 2-3% of children and may lead to problems with nighttime sleep and daytime behavior, learning, sleepiness, and mood. Adenotonsillectomy (AT) is the second most common surgical procedure in children. It is now performed more often for suspected SDB than for any other indication. However, recent studies indicate that many if not most children still have SDB after AT, and many still have learning or behavioral problems associated with SDB. The goals of this study are: (1) to assess the extent that behavior, cognition, and sleepiness in children can improve with Continuous positive airway pressure (CPAP) treatment after AT, and (2) to identify which patients stand to gain most from post-operative assessment and treatment.

Detailed Description

Obstructive sleep-disordered breathing (SDB) affects at least 2-3% of children and may have substantial adverse impact on behavior and cognition. Adenotonsillectomy (AT), the second most common surgical procedure in children, is now performed more often for suspected SDB than for any other indication. However, recent studies among an increasingly obese population now show something alarming: many if not most children still have SDB after AT, and many still suffer from residual neurobehavioral morbidity. Furthermore, the investigators' ongoing, 12-year, NIH-funded research has shown that standard preoperative polysomnographic measures of SDB do not consistently predict post-AT improvement in behavior and cognition. This may arise in part because many children after AT still have SDB, and because linear relationships between standard SDB measures and neurobehavioral morbidity may not exist. Even at subtle levels, SDB may promote significant neurobehavioral morbidity. Some have suggested that polysomnography may be more important after AT than before AT. However, in practice few children receive polysomnography before AT, and even fewer after AT, when continuous positive airway pressure (CPAP) could still provide definitive relief from SDB. Preliminary data from our group suggest that CPAP after AT is well-tolerated by most children and may provide significant benefit. However, virtually no published evidence exists to address critical clinical questions: which children benefit most from CPAP after AT; what role can clinical symptoms or polysomnography play in that determination; and what neurobehavioral gains are achieved by CPAP after AT?

The investigators therefore will undertake a highly practical, clinical study with two main goals: (1) to assess the extent that behavior, cognition, and sleepiness in children can improve with CPAP after AT, and (2) to identify which patients stand to gain most from post-operative assessment and treatment. This research will use reversible SDB-related neurobehavioral morbidity as the criteria by which to judge the utility of clinical symptoms and polysomnography in identification of candidates for CPAP after AT.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2012-03
• Study First Submitted: 2012-03-01
• Study First Submitted QC: 2012-03-14
• Study First Posted: 2012-03-15
• Primary Completion: 2017-10-29
• Study Completion: 2017-10-29
• Results First Submitted: 2018-10-26
• Status Verified: 2019-01
• Results First Submitted QC: 2019-01-10
• Last Update Submitted: 2019-01-10
• Results First Posted: 2019-01-14
• Last Update Posted: 2019-01-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

1. Children ages 5-12 years old,
2. Scheduled for an adenotonsillectomy for treatment of sleep apnea,
3. Child must provide assent, and
4. Parent or legal guardian must be able to speak and read English, and agree to the study.

Read More

Exclusion Criteria

1. No siblings of children already enrolled in the study,

2. Children who expect to have another surgery (in addition to AT) during the period of participation in this study,

3. Neurological, psychiatric, or medical conditions, or social factors that may affect test results, prevent children from returning for required study visits, or interfere with the study treatment, or

4. Certain medications that affect sleepiness or alertness, for example:

   • Stimulants (such as Ritalin, Adderall, or Concerta),
   • Sleep aides (such as Melatonin, Ambien, or Ativan), or
   • Sedating medicines (such as Benadryl, Klonopin, Xanax, or Valerian).

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
CPAP treatment	CPAP treatment	Children randomized to this arm will receive 6 months of CPAP (or BPAP) treatment, beginning at approximately 4 months after AT, in addition to standard of care. For analysis purposes those children who were non-adherent (CPAP use \<4 hours per night) vs. adherent (CPAP use at least 4 hours per night) will be analyzed separately.
No CPAP treatment	No CPAP treatment	Children randomized to this comparison arm will not be treated with CPAP or BPAP, but will be followed for approximately 10 months after AT while receiving standard of care.

Primary Outcome Measures

Name	Time	Method
Change in Behavioral Index After 6 Months of CPAP or No-CPAP	assessed as change from baseline to 6 months of CPAP therapy or no-CPAP	The sum of the T-scores of The Conners' Parent Rating Scales (CPRS-R:L, ADHD index) and the Child Behavior Checklist (CBCL, Attention Deficit/Hyperactivity Problems) are used to construct the primary study outcome measure Behavioral Index. Behavioral index is a T score (adjusted for age and gender) with a range of "\<10" to "\>90" - where higher scores mean worse behavior and lower scores mean better behavior, so a negative change score represents an improvement in behavior. T-scores with a mean of 50 and SD of 10 are computed.

Secondary Outcome Measures

Name	Time	Method
CPAP Adherence as Measured by Number of Participants Who Used the CPAP Consistently.	Starting at 4 months after AT and continuing through 10 months after AT	CPAP adherence data will be downloaded from CPAP machines. It is defined for this study as using the CPAP machine for at least an average of 4 hours per night during the last 60 days of the assignment.
Change in Quality of Life as Measured by Peds QL	assessed as change from baseline to 6 months of CPAP therapy or no-CPAP	Peds-QL is a quality of life symptom measurement with a score range of 0 to 100. Higher scores are better quality of life
Change in Cognition as Shown by NIH Toolbox Composite Score	assessed as change from baseline to 6 months of CPAP therapy or no-CPAP	Scores are reported as standardized scores with a mean of 100 and SD of 15. Minimum value 40 and Maximum value 160. Higher scores are better
Change in Sleepiness as Measured by Epworth Sleepiness Scale	assessed as change from baseline to 6 months of CPAP therapy or no-CPAP	Epworth Sleepiness Scale scores range from 0 to 24 where higher scores mean greater sleepiness.
Change in Sleepiness After AT as Measured by Multiple Sleep Latency Test (MSLT)	assessed as change from baseline to 6 months of CPAP therapy or no-CPAP	Multiple Sleep Latency Test (MSLT) is an objective measure of sleepiness determined by measure of brain waves and other physiological signals over a 30 minute period. This is measured for five 30 minute periods across the day and average latency to sleep for each participant across those times were used to calculate the mean sleep latency. The score is measured in how quickly one would fall asleep, measured in minutes, so a negative number of minutes in the change score means that participants fell asleep more quickly than previously.

Trial Locations

Locations (1)

University of Michigan Health System; 🇺🇸 Ann Arbor, Michigan, United States